BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

the antibody combines three targets, programmed cell death protein 1 (PD-1), vascular endothelial growth factor A (VEGFA), ...

CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four ...

(“BMS”). The claims of all three patents are directed to methods of treating cancer with the combination of two checkpoint inhibitor immunotherapeutic antibodies, anti-PD-1 and anti-CTLA-4.

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...